{"id":120158,"date":"2026-07-01T11:44:17","date_gmt":"2026-07-01T11:44:17","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/120158\/"},"modified":"2026-07-01T11:44:17","modified_gmt":"2026-07-01T11:44:17","slug":"novo-nordisk-nvo-upgraded-to-buy-at-nordea-here-is-why-3","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/120158\/","title":{"rendered":"Novo Nordisk (NVO) Upgraded to Buy at Nordea. Here is Why"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">With an annual dividend yield of 3.75%, Novo Nordisk A\/S (NYSE:<a href=\"https:\/\/finance.yahoo.com\/quote\/NVO\" data-ylk=\"slk:NVO;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;NVO&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"nofollow noopener\">NVO<\/a>)\u00a0is included among the <a href=\"https:\/\/www.insidermonkey.com\/blog\/12-best-nyse-stocks-to-buy-for-dividends-1791307\/\" data-ylk=\"slk:12%20Best%20NYSE%20Stocks%20to%20Buy%20for%20Dividends;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;12 Best NYSE Stocks to Buy for Dividends&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">12 Best NYSE Stocks to Buy for Dividends<\/a>.  <\/p>\n<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/C467C20FCAA18199596A46D4DFB3A5B47067C8B30FAC5F444C4B78DBA09F81C9\/subgraphmysterio\/resizefit_w960;quality_80;format_webp\/https:%2F%2Fmedia.zenfs.com%2Fen%2Finsidermonkey.com%2F8ee01456c2860ad756980e44c064cbb6\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Novo Nordisk (NVO) Upgraded to Buy at Nordea. Here is Why\" height=\"538\" width=\"960\" class=\"yf-lglytj loader\"\/><\/a> Novo Nordisk (NVO) Upgraded to Buy at Nordea. Here is Why           <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo Nordisk A\/S (NYSE:NVO) is a leading global healthcare company, founded in 1923 and headquartered in Denmark.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">On June 19, Nordea upgraded Novo Nordisk A\/S (NYSE:NVO) from &#8216;Hold&#8217; to &#8216;Buy&#8217; and assigned the stock a price target of DKK 350, implying an upside of 10% from the current levels.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The analyst firm expects the near-term news flow to be favorable for the pharma company. Nordea also believes that the sales of Novo&#8217;s Wegovy pill could exceed market expectations, further supporting its bullish sentiment.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Notably, on June 11, Novo Nordisk&#8217;s Wegovy pill became the first daily GLP-1 weight-loss pill approved in the UK. This paves the way for the Danish pharma giant to launch the drug in the second market outside the US this year, after the UAE regulator, Emirates Drug Establishment, already approved it earlier this month.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo has previously revealed plans to launch the product in select markets in the second half of 2026.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you&#8217;re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the<a href=\"https:\/\/www.insidermonkey.com\/blog\/three-megatrends-one-overlooked-stock-massive-upside-1548959\/\" data-ylk=\"slk:;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" class=\"fui-Link ___1q1shib f2hkw1w f3rmtva f1ewtqcl fyind8e f1k6fduh f1w7gpdv fk6fouc fjoy568 figsok6 f1s184ao f1mk8lai fnbmjn9 f1o700av f13mvf36 f1cmlufx f9n3di6 f1ids18y f1tx3yz7 f1deo86v f1eh06m1 f1iescvh fhgqx19 f1olyrje f1p93eir f1nev41a f1h8hb77 f1lqvz6u f10aw75t fsle3fq f17ae5zn\">\u00a0<\/a><a href=\"https:\/\/www.insidermonkey.com\/blog\/three-megatrends-one-overlooked-stock-massive-upside-1548959\/\" data-ylk=\"slk:best%20short-term%20AI%20stock;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;best short-term AI stock&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" class=\"fui-Link ___1q1shib f2hkw1w f3rmtva f1ewtqcl fyind8e f1k6fduh f1w7gpdv fk6fouc fjoy568 figsok6 f1s184ao f1mk8lai fnbmjn9 f1o700av f13mvf36 f1cmlufx f9n3di6 f1ids18y f1tx3yz7 f1deo86v f1eh06m1 f1iescvh fhgqx19 f1olyrje f1p93eir f1nev41a f1h8hb77 f1lqvz6u f10aw75t fsle3fq f17ae5zn\">best short-term AI stock<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">READ NEXT:\u00a0<a href=\"https:\/\/www.insidermonkey.com\/blog\/12-best-nasdaq-stocks-to-buy-for-dividends-1789460\/\" data-ylk=\"slk:12%20Best%20NASDAQ%20Stocks%20to%20Buy%20for%20Dividends;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;12 Best NASDAQ Stocks to Buy for Dividends&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">12 Best NASDAQ Stocks to Buy for Dividends<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.insidermonkey.com\/blog\/12-best-sp-500-stocks-to-buy-for-dividends-1788140\/\" data-ylk=\"slk:12%20Best%20S%26P%20500%20Stocks%20to%20Buy%20for%20Dividends;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;12 Best S&amp;P 500 Stocks to Buy for Dividends&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">12 Best S&amp;P 500 Stocks to Buy for Dividends<\/a>  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Disclosure: None. <a href=\"https:\/\/news.google.com\/publications\/CAAqLQgKIidDQklTRndnTWFoTUtFV2x1YzJsa1pYSnRiMjVyWlhrdVkyOXRLQUFQAQ?hl=en-US&amp;gl=US&amp;ceid=US%3Aen\" data-ylk=\"slk:Follow%20Insider%20Monkey%20on%20Google%20News;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Follow Insider Monkey on Google News&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Follow Insider Monkey on Google News<\/a>.  <\/p>\n","protected":false},"excerpt":{"rendered":"With an annual dividend yield of 3.75%, Novo Nordisk A\/S (NYSE:NVO)\u00a0is included among the 12 Best NYSE Stocks&hellip;\n","protected":false},"author":2,"featured_media":120159,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[46617,272,59481],"class_list":["post-120158","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-nordea","tag-novo-nordisk","tag-pharma-company"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116844551740653794","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/120158","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=120158"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/120158\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/120159"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=120158"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=120158"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=120158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}